報價延遲最少15分鐘:2024/06/13 04:18 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.28 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.91/-0.85
|
|
企業價值
330.38M
|
| 資產負債 |
|
每股賬面淨值
0.69
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
90.12M
|
|
每股收益
0.48
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/06/13 04:18 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people.The group derives revenue from the United States and the Rest of the World. |